A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Primary Breast Cancer
Interventions: DRUG: Myocet|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Sponsor: West German Study Group
Collaborators: Teva Pharmaceuticals USA